Trends In Reported Outcomes for Growth Hormone Therapy In Children With Growth Hormone Deficiency
Authors' conclusion
The results of this systematic review allow the development of a core outcome set that is recommended for routine use in all children receiving rhGH for childhood GHD.
Study context
- Population
- Studies of children who started rhGH before age 16 years for growth hormone deficiency (GHD); median age at start of rhGH 9.5 years (10th-90th: 7.1–11.9)
- Participants
- 219 eligible studies
- Outcome
- Frequency and trends in reported outcomes of safety and effectiveness for rhGH therapy for childhood GHD
Methodological details7 English- and Chinese-language databases, studies published 2003–2022
- 7 English- and Chinese-language databases
- Studies published 2003–2022
Pooled result
As reported in the abstract
Most commonly reported outcomes (studies reporting)
- Change in height SDS
- 117 (53%)
- Height velocity
- 105 (48%)
- IGF-1
- 66 (30%)
- Height
- 63 (29%)
- Bone age
- 58 (26%)
- IGF-1 SDS
- 45 (21%)
- Injection site adverse events
- 44 (20%)
- Glucose concentration
- 42 (19%)
- Insulin-like growth factor-binding protein 3
- 34 (16%)
- Thyroid function
- 30 (14%)
- Of 342 different outcomes, mainly safety-focused
- 178 (52%)
- Of 342 outcomes, mainly efficacy-focused
- 94 (28%)
- Of 342 outcomes, both safety and efficacy
- 70 (20%)
Further pooled results
- Quality-of-life outcomes among 342 outcomes
- 9 (3%)
- Studies reporting quality of life
- 29 of 219 (13%)
Original publication
Trends In Reported Outcomes for Growth Hormone Therapy In Children With Growth Hormone Deficiency. J Clin Endocrinol Metab. Published 5 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →